

**Food and Drug Administration
Center for Drug Evaluation and Research**

Oncologic Drugs Advisory Committee

72nd Meeting

Holiday Inn
8777 Georgia Avenue
Silver Spring, Maryland

DRAFT Agenda

September 24, 2002

8:30	Call to Order and Opening Remarks	Donna Przepiorka, M.D., Ph.D. Chair, ODAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Executive Secretary, ODAC
	Open Public Hearing	

NDA 21-399, IRESSA[®] (gefitinib), AstraZeneca Pharmaceuticals LP

- indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy

9:45	Sponsor Presentation	AstraZeneca Pharmaceuticals LP
10:45	Break	
11:00	FDA Presentation	
11:45	Questions from the Committee	
12:45	Lunch	
1:45	Committee Discussion and Vote	
4:00	Adjourn	